( MENAFN - GetNews) The NSCLC drug market is driven by advancements in targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), which offer improved efficacy and tolerability compared to traditional chemotherapy. According to the latest research study , the demand of global Non-Small-Cell Lung Cancer Drug Market size & share was valued at approximately USD 31,614.8 Million in 2023 and is expected to reach USD 34,175.
6 Million in 2024 and is expected to reach a value of around USD 68,888.6 Million by 2033, at a compound annual growth rate (CAGR) of about 8.1% during the forecast period 2024 to 2033.
MAIA Biotechnology, Inc. (NYSE American: MAIA) , a trailblazer in clinical-stage biopharmaceuticals, revealed impressive efficacy data from the Phase 2 THIO-101 clinical trial of THIO in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) for treating advanced non-small cell lung cancer (NSCLC). The latest findings, which were showcased during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, demonstrate significant superiority over standard-of-care therapies, particularly in patients who have undergone multiple prior treatments.
The updated trial results revealed a notable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% with the THIO + cemiplimab combination in third-line treatments-figures that starkly outpace the standard-of-care ORR of 6–10% and DCR of 25–35% typica.
